非临床信息在更新动态推荐中的重要性:澳大利亚动态COVID-19临床指南案例研究
该研究回顾性分析了澳大利亚动态COVID-19临床指南中基于非临床来源的信息更新,共识别302项非临床变更,多数涉及推荐支持信息、推荐文本和患者偏好与价值观,最常见来源为专家共识,并指出开发者应考虑将非临床信息作为判断是否适合动态指南的第四项关键标准。
要点
- 动态指南更新不仅依赖原始临床研究证据,非临床信息同样重要。
- 3年内共发生302项非临床变更,专家共识是最常见来源。
- 建议将非临床信息作为判断是否采用动态指南方法的第四项关键标准。
核心结论
- 非临床来源信息在动态指南更新中数量大、来源多样,对推荐的可应用性、适宜性和可实施性至关重要。
- 开发者应考虑基于非临床信息的第四项关键标准,以判断是否适合采用动态指南方法。
研究设计与样本
- 回顾性识别并提取澳大利亚动态COVID-19临床指南中所有非临床信息更新,记录变更位置、来源和原因。
主要发现
- 3年期间共发生302项非临床变更。
- 多数变更涉及推荐的支持信息(46%)、推荐文本(26%)或患者偏好与价值观(18%)。
- 最常见变更来源为专家共识(50%)。
- 在托珠单抗供应及针对SARS-CoV-2奥密克戎亚变异株的单克隆抗体体外活性降低证据等领域发生了有影响力的变更。
临床怎么用
- 在动态指南迭代中应与广泛利益相关者互动,以获取非临床信息。
- 更新推荐时需系统纳入专家共识、患者偏好及政策等非临床信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Living guidelines facilitate optimized patient care by providing up-to-date, evidence-based recommendations. Although a strong focus has been placed on the updating of living recommendations using clinical evidence from primary studies, the inclusion of contextualizing information from nonclinical sources is equally important in maximizing the applicability, appropriateness, and implementability of living recommendations. We aimed to examine the range and impact of changes to the Australian Living COVID-19 Clinical Guidelines based on information from nonclinical sources. STUDY DESIGN AND SETTING: We retrospectively identified and extracted all nonclinical information updates (ie, updates to the guideline based on information other than direct primary studies, approval or supply of therapeutics) to the COVID-19 guidelines. For each update, we recorded the location in the guideline where the change was made (eg, recommendation, evidence-to-decision), source of change (eg, expert consensus, consumer input, and government/policy decision), and reason for change (eg, approval/supply of therapeutics, clarity around population). Additional information was collected for specific high-impact nonclinical evidence updates. RESULTS: A total of 302 nonclinical changes were made to the guidelines across a 3-year period. The majority of changes were made to the additional information underpinning recommendations (46%), text of the recommendation (26%), or patient preferences and values (18%), with the most prevalent source of change being expert consensus (50%). Several impactful changes were made in areas such as tocilizumab supply and in vitro evidence regarding reduced activity of monoclonal antibodies against SARS-CoV-2 Omicron subvariants. CONCLUSION: Our analysis highlights the significant quantity and diversity of information captured and incorporated within the COVID-19 clinical guidelines from nonclinical sources. Engagement with a broad range of interest holders across living guideline iterations is integral to acquiring this information, and developers should consider a fourth key criterion, based on nonclinical information, to determine whether a living approach is appropriate.
引用
- White H, Turner T, McDonald S, et al. The importance of non-clinical information in updating living recommendations: a case study of the Australian living COVID-19 clinical guidelines. J Clin Epidemiol. 2026. PMID: 42302881. doi:10.1016/j.jclinepi.2026.112384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。